|
1
|
Chidambaran V, Costandi A and D'Mello A:
Correction to: Propofol: A review of its role in pediatric
anesthesia and sedation. CNS Drugs. 32:8732018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siddiqui RA, Zerouga M, Wu M, Castillo A,
Harvey K, Zaloga GP and Stillwell W: Anticancer properties of
propofol-docosahexaenoate and propofol-eicosapentaenoate on breast
cancer cells. Breast Cancer Res. 7:R645–R654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cui WY, Liu Y, Zhu YQ, Song T and Wang QS:
Propofol induces endoplasmic reticulum (ER) stress and apoptosis in
lung cancer cell H460. Tumour Biol. 35:5213–5217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang ZT, Gong HY, Zheng F, Liu DJ and Dong
TL: Propofol suppresses proliferation and invasion of pancreatic
cancer cells by upregulating microRNA-133a expression. Genet Mol
Res. 14:7529–7537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang P, Chen J, Mu LH, Du QH, Niu XH and
Zhang MY: Propofol inhibits invasion and enhances
paclitaxel-induced apoptosis in ovarian cancer cells through the
suppression of the transcription factor slug. Eur Rev Med Pharmacol
Sci. 17:1722–1729. 2013.PubMed/NCBI
|
|
6
|
Zhang J, Shan WF, Jin TT, Wu GQ, Xiong XX,
Jin HY and Zhu SM: Propofol exerts anti-hepatocellular carcinoma by
microvesicle-mediated transfer of miR-142-3p from macrophage to
cancer cells. J Transl Med. 12:2792014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang C, Gao J, Yan N, Wu B, Ren Y, Li H
and Liang J: Propofol inhibits the growth and survival of gastric
cancer cells in vitro through the upregulation of ING3.
Oncol Rep. 37:587–593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng Z and Zhang Y: Propofol inhibits
proliferation and accelerates apoptosis of human gastric cancer
cells by regulation of microRNA-451 and MMP-2 expression. Genet Mol
Res. 15:2016. View Article : Google Scholar
|
|
9
|
Ebbesen KK, Hansen TB and Kjems J:
Insights into circular RNA biology. RNA Biol. 14:1035–1045. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Yang L and Chen LL: Life without
A tail: New formats of long noncoding RNAs. Int J Biochem Cell
Biol. 54:338–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonizzato A, Gaffo E, Te Kronnie G and
Bortoluzzi S: CircRNAs in hematopoiesis and hematological
malignancies. Blood Cancer J. 6:e4832016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dykes IM and Emanueli C: Transcriptional
and post-transcriptional gene regulation by long non-coding RNA.
Genomics Proteomics Bioinformatics. 15:177–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He T, Li X, Xie D and Tian L:
Overexpressed circPVT1 in oral squamous cell carcinoma promotes
proliferation by serving as a miRNA sponge. Mol Med Rep.
20:3509–3518. 2019.PubMed/NCBI
|
|
14
|
Verduci L, Ferraiuolo M, Sacconi A, Ganci
F, Vitale J, Colombo T, Paci P, Strano S, Macino G, Rajewsky N and
Blandino G: The oncogenic role of circPVT1 in head and neck
squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD
transcription-competent complex. Genome Biol. 18:2372017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
Overexpressed circPVT1, a potential new circular RNA biomarker,
contributes to doxorubicin and cisplatin resistance of osteosarcoma
cells by regulating ABCB1. Int J Biol Sci. 14:321–330. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Li Y, Zheng Q, Bao C, He J, Chen
B, Lyu D, Zheng B, Xu Y, Long Z, et al: Circular RNA profile
identifies circPVT1 as a proliferative factor and prognostic marker
in gastric cancer. Cancer Lett. 388:208–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YY, Zhang LY and Du WZ: Circular RNA
circ-PVT1 contributes to paclitaxel resistance of gastric cancer
cells through the regulation of ZEB1 expression by sponging
miR-124-3p. Biosci Rep. 39:BSR201930452019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pang JC, Kwok WK, Chen Z and Ng HK:
Oncogenic role of microRNAs in brain tumors. Acta Neuropathol.
117:599–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mott JL: MicroRNAs involved in tumor
suppressor and oncogene pathways: Implications for hepatobiliary
neoplasia. Hepatology. 50:630–637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tutar Y, Özgür A, Tutar E, Tutar L,
Pulliero A and Izzotti A: Regulation of oncogenic genes by
MicroRNAs and pseudogenes in human lung cancer. Biomed
Pharmacother. 83:1182–1190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nie H, Mu J, Wang J and Li Y: miR1955p
regulates multidrug resistance of gastric cancer cells via
targeting ZNF139. Oncol Rep. 40:1370–1378. 2018.PubMed/NCBI
|
|
22
|
Wang F, Ruan L, Yang J, Zhao Q and Wei W:
TRIM14 promotes the migration and invasion of gastric cancer by
regulating epithelial-to-mesenchymal transition via activation of
AKT signaling regulated by miR1955p. Oncol Rep. 40:3273–3284.
2018.PubMed/NCBI
|
|
23
|
Wang J, Li L, Jiang M and Li Y:
MicroRNA-195 inhibits human gastric cancer by directly targeting
basic fibroblast growth factor. Clin Transl Oncol. 19:1320–1328.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao DL and Wu QL: Effect of inhibition to
Yes-related proteins-mediated Wnt/β-catenin signaling pathway
through miR-195-5p on apoptosis of gastric cancer cells. Eur Rev
Med Pharmacol Sci. 23:6486–6496. 2019.PubMed/NCBI
|
|
25
|
Yordy JS and Muise-Helmericks RC: Signal
transduction and the Ets family of transcription factors. Oncogene.
19:6503–6513. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu D, Wilson TJ, Chan D, De Luca E, Zhou
J, Hertzog PJ and Kola I: Ets1 is required for p53 transcriptional
activity in UV-induced apoptosis in embryonic stem cells. EMBO J.
21:4081–4093. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wolvetang EJ, Wilson TJ, Sanij E,
Busciglio J, Hatzistavrou T, Seth A, Hertzog PJ and Kola I: ETS2
overexpression in transgenic models and in Down syndrome
predisposes to apoptosis via the p53 pathway. Hum Mol Genet.
12:247–255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Lu JY, Zhao LQ, Wang XQ, Liu GL, Liu
Z, Zhou CN, Wu M and Liu ZH: Overexpression of ETS2 in human
esophageal squamous cell carcinoma. World J Gastroenterol.
9:205–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou J, Ng AY, Tymms MJ, Jermiin LS, Seth
AK, Thomas RS and Kola I: A novel transcription factor, ELF5,
belongs to the ELF subfamily of ETS genes and maps to human
chromosome 11p13-15, a region subject to LOH and rearrangement in
human carcinoma cell lines. Oncogene. 17:2719–2732. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li D, Chen Y, Mei H, Jiao W, Song H, Ye L,
Fang E, Wang X, Yang F, Huang K, et al: Ets-1 promoter-associated
noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric
cancer progression. Oncogene. 37:4871–4886. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baillat D, Bègue A, Stéhelin D and
Aumercier M: ETS-1 transcription factor binds cooperatively to the
palindromic head to head ETS-binding sites of the stromelysin-1
promoter by counteracting autoinhibition. J Biol Chem.
277:29386–29398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rutter JL, Mitchell TI, Butticè G, Meyers
J, Gusella JF, Ozelius LJ and Brinckerhoff CE: A single nucleotide
polymorphism in the matrix metalloproteinase-1 promoter creates an
Ets binding site and augments transcription. Cancer Res.
58:5321–5325. 1998.PubMed/NCBI
|
|
33
|
Nakada M, Yamashita J, Okada Y and Sato H:
Ets-1 positively regulates expression of urokinase-type plasminogen
activator (uPA) and invasiveness of astrocytic tumors. J
Neuropathol Exp Neurol. 58:329–334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Trojanowska M: Ets factors and regulation
of the extracellular matrix. Oncogene. 19:6464–6471. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Z and Klominek J: Regulation of matrix
metalloprotease activity in malignant mesothelioma cell lines by
growth factors. Thorax. 58:198–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fink K and Boratyński J: The role of
metalloproteinases in modification of extracellular matrix in
invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med
Dosw (Online). 66:609–628. 2012.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nazir SU, Kumar R, Singh A, Khan A, Tanwar
P, Tripathi R, Mehrotra R and Hussain S: Breast cancer invasion and
progression by MMP-9 through Ets-1 transcription factor. Gene.
711:1439522019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Q, Liu H, Cheng H, Li Y, Li X and Zhu
C: Downregulation of long noncoding RNA TUG1 inhibits proliferation
and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder
cancer cells. Onco Targets Ther. 10:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang W, Wang Y, Zhu Z, Zheng Y and Song
B: Propofol inhibits proliferation, migration and invasion of
gastric cancer cells by up-regulating microRNA-195. Int J Biol
Macromol. 120:975–984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pisonero-Vaquero S, Soldati C, Cesana M,
Ballabio A and Medina DL: TFEB modulates p21/WAF1/CIP1 during the
DNA damage response. Cell. 9:11862020. View Article : Google Scholar
|
|
42
|
Skommer J, Brittain T and Raychaudhuri S:
Bcl-2 inhibits apoptosis by increasing the time-to-death and
intrinsic cell-to-cell variations in the mitochondrial pathway of
cell death. Apoptosis. 15:1223–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Wang C, Li Q, Guo C, Sun W, Zhao
D, Jiang S, Hao L, Tian Y, Liu S and Sun MZ: miR-429-CRKL axis
regulates clear cell renal cell carcinoma malignant progression
through SOS1/MEK/ERK/MMP2/MMP9 pathway. Biomed Pharmacother.
127:1102152020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang R, Xing L, Zheng X, Sun Y, Wang X and
Chen J: The circRNA circAGFG1 acts as a sponge of miR-195-5p to
promote triple-negative breast cancer progression through
regulating CCNE1 expression. Mol Cancer. 18:42019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chou NH, Lo YH, Wang KC, Kang CH, Tsai CY
and Tsai KW: MiR-193a-5p and −3p play a distinct role in gastric
cancer: miR-193a-3p suppresses gastric cancer cell growth by
targeting ETS1 and CCND1. Anticancer Res. 38:3309–3318. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu Y, Zhang YC, Zhang WZ, Shen LS, Hertzog
P, Wilson TJ and Xu DK: Ets1 as a marker of malignant potential in
gastric carcinoma. World J Gastroenterol. 9:2154–2159. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng L, Qi T, Yang D, Qi M, Li D, Xiang
X, Huang K and Tong Q: microRNA-9 suppresses the proliferation,
invasion and metastasis of gastric cancer cells through targeting
cyclin D1 and Ets1. PLoS One. 8:e557192013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meng S, Jian Z, Yan X, Li J and Zhang R:
LncRNA SNHG6 inhibits cell proliferation and metastasis by
targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
Mol Med Rep. 20:2541–2548. 2019.PubMed/NCBI
|
